What is the Agios Pharmaceuticals Inc. stock price forecast?

Agios Pharmaceuticals Inc. is currently trading at $29.46. View real-time AI analysis on Alpha Lenz.

What is Agios Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Agios Pharmaceuticals Inc. on Alpha Lenz.

What is Agios Pharmaceuticals Inc.'s P/E ratio?

Agios Pharmaceuticals Inc.'s P/E ratio is -4.1.

Agios Pharmaceuticals Inc.

NASDAQ · AGIO

$29.46+0.74(+2.58%)Pre-market

Ask about Agios Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Agios Pharmaceuticals Inc. trades at a P/E of -4.1 (undervalued) with modest ROE of -30.2%. 3Y revenue CAGR of 56.0% highlights clear growth momentum.”

Ask for details →

Company Overview

Agios Pharmaceuticals Inc. is a biopharmaceutical company dedicated to pioneering the development of innovative therapies for genetically defined diseases. The core focus of Agios is to leverage the science of cellular metabolism to develop transformative treatments for patients. Key areas of impact include hematological malignancies and rare genetic diseases, where the company has made significant strides in understanding and targeting the metabolic pathways that drive disease. Agios Pharmaceuticals conducts extensive research to identify and advance drug candidates, optimizing their potential impact on improving patient outcomes. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company operates within the burgeoning biotech and healthcare sectors, contributing to revolutionary advances in medical treatments. Agios’ commitment to research excellence and its focus on unmet medical needs underscore its significance in the biotechnology market, positioning it as a notable player in the field of next-generation therapeutic development.

CEOMr. Brian M. Goff M.B.A.

Websitehttps://www.agios.com

SectorHealthcare

IndustryBiotechnology

Employees486

Company Statistics

FY 2025

Profile

$1.71BMarket Cap

$54.03MRevenue

0.00Shares Out

486Employees

Margins

88.26%Gross

-864.28%EBITDA

-873.87%Operating

-765.89%Pre-Tax

-764.01%Net

Valuation

-4.14P/E

1.43P/B

31.61EV/Sales

-3.55EV/EBITDA

-4.41P/FCF

Growth (CAGR)

55.97%Rev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-27.89%ROA

-30.20%ROE

-31.90%ROIC

Financial Health

$89.13MCash & Cash Equivalents

$14.98MNet Debt

8.73%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Agios Pharmaceuticals Inc. trades at a P/E of -4.1 (undervalued) with modest ROE of -30.2%. 3Y revenue CAGR of 56.0% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Agios Pharmaceuticals Inc. (ticker: AGIO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 486 employees. Market cap is $1.7B.

The current price is $29.46 with a P/E ratio of -4.14x and P/B of 1.43x.

ROE is -30.20% and operating margin is -873.87%. Annual revenue is $54M.